GlassScriptPhysician profile
Mohammed Salhab
NPI 1831454149
$7,190.19
in general payments reported to CMS, 2019-2025
49 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $76.86 · 2021: $1,832 · 2022: $1,957 · 2023: $497 · 2024: $2,453 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,458 · Travel and Lodging: $718 · Education: $46.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,458.33 |
| Travel and Lodging | $717.73 |
| Education | $46.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,123.84 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq, Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial), Therasphere Administration Set |
| Janssen Biotech, INC. | $1,780.96 | 2021-2024 | Imbruvica, Tecvayli, Darzalex |
| Genzyme Corporation | $293.83 | 2020-2023 | |
| Alexion Pharmaceuticals, INC. | $273.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $220.69 | 2020-2025 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Genmab U.S., INC. | $174.99 | 2023-2025 | Epkinly, Tivdak |
| Amgen INC. | $173.15 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Exelixis INC. | $136.30 | 2021-2024 | Cabometyx |
| Pfizer INC. | $131.15 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $122.22 | 2021-2024 | Enhertu |
| Aveo Pharmaceuticals, INC. | $99.18 | 2021-2022 | |
| Myovant Sciences INC. | $95.78 | 2021-2022 | |
| Abbvie INC. | $70.49 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $69.31 | 2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Salhab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.